Meropenem (Monograph)
Brand name: Merrem
Drug class: Carbapenems
Chemical name: [4R-[3(3S*,5S*),4α,5β,6β(R)]]-3-[[5- [(Dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate
Molecular formula: C17H25N3O5S•3H2OC17H25N3O5S
CAS number: 119478-56-7
Introduction
Antibacterial; carbapenem β-lactam antibiotic.1 2 3
Uses for Meropenem
Intra-abdominal Tract Infections
Treatment of intra-abdominal infections (complicated appendicitis, peritonitis) caused by susceptible viridans streptococci, Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, or Peptostreptococcus.1 2 3 4 6 7 9 10 12 24 28 43
Has a broad spectrum of antibacterial activity against both aerobes and anaerobes; may be used empirically to treat intra-abdominal infections before identification of the causative organism.1 2 6 7 10
For immunosuppressed patients or those with severe intra-abdominal infections, IDSA recommends an initial empiric regimen with broad spectrum of activity such as meropenem or imipenem; a third or fourth generation cephalosporin (cefepime, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone) in conjunction with metronidazole; ciprofloxacin in conjunction with metronidazole; piperacillin-tazobactam; or aztreonam in conjunction with metronidazole.28 For mild to moderate community-acquired intra-abdominal infections, IDSA recommends an initial empiric regimen with narrower spectrum of activity such as ampicillin-sulbactam; cefazolin or cefuroxime in conjunction with metronidazole; ticarcillin-clavulanate; ertapenem; or a fluoroquinolone (ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin) in conjunction with metronidazole.28
For postoperative (nosocomial) intra-abdominal infections, IDSA recommends the empiric regimen be selected based on local nosocomial susceptibility patterns; these infections usually require treatment with multiple-drug regimens and often involve resistant organisms.28
Meningitis
Treatment of bacterial meningitis caused by susceptible Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), or Neisseria meningitidis in children ≥3 months of age.1 2 8 10 Also has been used for treatment of meningitis in adults† [off-label].29 46
Efficacy for treatment of meningitis caused by highly penicillin- or cephalosporin-resistant S. pneumoniae has not been established.1 29 44 45
Can be used as monotherapy for meningitis caused by susceptible bacteria.1 Although not usually considered initial drug of choice,24 25 29 30 recommended as an alternative in children and adults for treatment of meningitis caused by S. pneumoniae or H. influenzae.24 25 29 30 Also may be useful for meningitis caused by susceptible gram-negative bacteria (e.g., Enterobacter† [off-label], Citrobacter† [off-label], Serratia marcescens† [off-label]) resistant to usually recommended regimens.29
Respiratory Tract Infections
Treatment of respiratory tract infections† [off-label], including community-acquired pneumonia (CAP) and nosocomial pneumonia.19 20 21 22 23 24 26 27
ATS, IDSA, and others consider meropenem an alternative, not a drug of first choice, for empiric treatment of CAP† caused by S. pneumoniae.19 20 23 26 ATS and IDSA suggest the drug be reserved for when CAP may be caused by Ps. aeruginosa,20 23 Klebsiella,23 or other gram-negative bacteria.23 Also may be considered when anaerobes are known or suspected to be involved.19
A drug of choice for empiric treatment of nosocomial pneumonia†.24 26 ATS, IDSA, and others recommend an antipseudomonal cephalosporin (cefepime, ceftazidime), antipseudomonal penicillin (piperacillin-tazobactam, ticarcillin-clavulanate), or antipseudomonal carbapenem (imipenem or meropenem) for initial therapy of hospital-acquired pneumonia, ventilator-associated pneumonia, or health-care associated pneumonia because these drugs have broad spectrum of activity against gram-positive, gram-negative, and anaerobic bacteria.24 26 27 In severely ill patients or in those with late-onset disease or risk factors for multidrug-resistant bacteria, initial regimen should also include an aminoglycoside (amikacin, gentamicin, tobramycin) or antipseudomonal fluoroquinolone (ciprofloxacin or levofloxacin) to improve coverage against Pseudomonas.24 26 In hospitals where oxacillin-resistant (methicillin-resistant) Staphylococcus are common or if there are risk factors for these strains, the initial regimen also should include vancomycin or linezolid.24 26 27 In hospitals where multidrug-resistant Ps. aeruginosa are frequent causes of nosocomial pneumonia, an initial regimen of cefepime or a carbapenem (imipenem or meropenem) in conjunction with an aminoglycoside is recommended.26 54
Septicemia
Treatment of septicemia† caused by susceptible bacteria.24
Skin and Skin Structure Infections
Treatment of complicated skin and skin structure infections caused by susceptible S. aureus (including β-lactamase-producing strains, but not oxacillin-resistant [methicillin-resistant] strains), S. pyogenes (group A β-hemolytic streptococci), S. agalactiae (group B streptococci), viridans streptococci, Enterococcus faecalis (not vancomycin-resistant strains), Ps. aeruginosa, E. coli, Proteus mirabilis, B. fragilis, or Peptostreptococcus.1
Urinary Tract Infections
Treatment of complicated urinary tract infections† caused by susceptible bacteria.38
Acinetobacter Infections
Treatment of infections caused by Acinetobacter†;24 a drug of choice used with or without an aminoglycoside.24
Anthrax
Recommended as one of several anti-infectives that can be included in multiple-drug regimens used for the treatment of anthrax†, including inhalational anthrax and anthrax meningitis.31 39
Has in vitro activity against Bacillus anthracis; data not available regarding in vivo activity.40
Bacillus Infections
Treatment of infections caused by Bacillus cereus†.24 Vancomycin considered drug of choice; carbapenems (imipenem or meropenem) or clindamycin are alternatives.24
Burkholderia Infections
Treatment of melioidosis† caused by Burkholderia pseudomallei.24 31 32 33 34 Severe illness requires an initial parenteral regimen of ceftazidime, imipenem, or meropenem (with or without concomitant co-trimoxazole or doxycycline), followed by a prolonged oral maintenance regimen of co-trimoxazole in conjunction with doxycycline or amoxicillin-clavulanate.31 34
Treatment of glanders† caused by B. mallei.31 34 Experience is limited regarding treatment of human cases; optimum regimens not identified.31 34 Some clinicians suggest streptomycin used in conjunction with tetracycline or chloramphenicol or imipenem monotherapy.24 Others suggest that, pending results of in vitro susceptibility tests, regimens used for treatment of melioidosis can be used for initial empiric treatment of glanders.34
The US Army Medical Research Institute of Infectious Diseases (USAMRIID) and European Commission’s Task Force on Biological and Chemical Agent Threats (BICHAT) state that the same treatment regimens recommended for naturally occurring melioidosis or glanders should be used if these Burkholderia infections occur in the context of biologic warfare or bioterrorism.31 34 These experts suggest that postexposure prophylaxis with doxycycline or co-trimoxazole for ≥10 days can be attempted in such situations, but is of unproven benefit.31 34
Campylobacter Infections
Treatment of systemic infections caused by Campylobacter fetus†;24 a drug of choice.24
Capnocytophaga Infections
Treatment of infections caused by Capnocytophaga canimorsus†.24
Optimum regimens for treatment of Capnocytophaga infections not identified; some clinicians recommend use of penicillin G or, alternatively, a third generation cephalosporin (cefotaxime, ceftizoxime, ceftriaxone), a carbapenem (imipenem or meropenem), vancomycin, a fluoroquinolone, or clindamycin.24
Clostridium Infections
Treatment of infections caused by Clostridium perfringens†; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.24 25
Nocardia Infections
Treatment of infections caused by Nocardia†.24 25 Co-trimoxazole usually drug of first choice;24 alternatives include sulfisoxazole, a tetracycline (e.g., doxycycline, minocycline), a carbapenem (imipenem or meropenem), amikacin, ceftriaxone, amoxicillin-clavulanate, cycloserine, or linezolid.24 25
Rhodococcus Infections
Treatment of infections caused by Rhodococcus equi†.24 Optimum regimens not identified; combination regimens usually recommended, including vancomycin given with a fluoroquinolone, rifampin, a carbapenem (imipenem or meropenem), or amikacin.24
Empiric Therapy in Febrile Neutropenic Patients
Empiric anti-infective therapy of presumed bacterial infections in febrile neutropenic patients†.14 24 Used alone or in conjunction with other anti-infectives.14 24
Consult published protocols for the treatment of infections in febrile neutropenic patients for specific recommendations regarding selection of the initial empiric regimen, when to change the initial regimen, possible subsequent regimens, and duration of therapy in these patients.14 Consultation with an infectious disease expert knowledgeable about infections in immunocompromised patients also is advised.14
Meropenem Dosage and Administration
Administration
Administer by IV injection or infusion.1
For solution and drug compatibility information, see Compatibility under Stability.
IV Injection
Reconstitution
Reconstitute single-use vials containing 500 mg or 1 g with 10 or 20 mL, respectively, of sterile water for injection to provide a solution containing approximately 50 mg/mL.1 The vial should be shaken until dissolution occurs and then allowed to stand until the solution is clear.1
Rate of Administration
The appropriate dose of reconstituted solution should be injected over a period of 3–5 minutes.1
IV Infusion
Reconstitution and Dilution
Reconstitute infusion vials containing 500 mg or 1 g with a compatible IV solution (e.g., 0.9% sodium chloride, 5% dextrose) to provide solutions containing approximately 2.5–50 mg/mL.1 Alternatively, reconstitute vials containing 500 mg or 1 g with 10 or 20 mL, respectively, of sterile water for injection and then further dilute in a compatible IV.1
Rate of Administration
Infuse IV over 15–30 minutes.1
Dosage
Available as the trihydrate; dosage expressed in terms of anhydrous meropenem.13
To minimize risk of seizures, closely adhere to dosage recommendations, especially in patients with factors known to predispose to seizure activity; dosage adjustment recommended for patients with advanced age and/or renal impairment.1
Anticonvulsant therapy should be continued in patients with existing seizure disorders.1 (See CNS Effects under Cautions.)
Pediatric Patients
Intra-abdominal Infections
IV
Children ≥3 months of age weighing ≤50 kg: 20 mg/kg (up to 1 g) every 8 hours.1 2
Children ≥3 months weighing >50 kg: 1 g every 8 hours.1
Meningitis
IV
Children ≥3 months of age weighing ≤50 kg: 40 mg/kg (up to 2 g) every 8 hours.1 2
Children ≥3 months weighing >50 kg: 2 g every 8 hours.1
Skin and Skin Structure Infections
IV
Children ≥3 months of age weighing ≤50 kg: 10 mg/kg (up to 500 mg) every 8 hours.1
Children ≥3 months weighing >50 kg: 500 mg every 8 hours.1
Burkholderia Infections†
Initial Treatment of Severe Disease†
IVChildren ≥3 months of age weighing ≤40 kg: 10–20 mg/kg every 8 hours.34
Children ≥3 months weighing >40 kg: use adult dosage.34
Initial IV regimen continued for ≥14 days and until clinical improvement occurs.31 34 When appropriate, switch to a prolonged oral maintenance regimen (e.g., co-trimoxazole with doxycycline, amoxicillin-clavulanate).31 34 Lifelong follow-up recommended for all patients to identify relapse.31
Adults
Intra-abdominal Infections
IV
1 g every 8 hours.1
Meningitis†
IV
6 g daily.29 Dosage of 40 mg/kg every 8 hours (up to 6 g daily) has been used in conjunction with ceftriaxone or cefotaxime.46
Respiratory Tract Infections†
Nosocomial Pneumonia†
IV1 g every 8 hours.27
Skin and Skin Structure Infections
IV
500 mg every 8 hours.1
Burkholderia Infections†
Initial Treatment of Severe Disease†
IV25 mg/kg IV every 8 hours (up to 6 g daily) recommended by USAMRIID and others; concomitant co-trimoxazole (8 mg/kg of trimethoprim daily given IV in 4 divided doses) also may be indicated.31 32 33 Other clinicians recommend 0.5–1 g every 8 hours with or without co-trimoxazole.34
Initial IV regimen continued for ≥14 days and until clinical improvement occurs.31 34 When appropriate, switch to a prolonged oral maintenance regimen (e.g., co-trimoxazole with doxycycline, amoxicillin-clavulanate).31 34 Lifelong follow-up recommended for all patients to identify relapse.31
Prescribing Limits
Pediatric Patients
IV
2 g every 8 hours.1
Special Populations
Hepatic Impairment
Dosage adjustments not required.1
Renal Impairment
Dosage adjustments recommended in adults with Clcr ≤50 mL/minute.1 Data insufficient to make dosage recommendations for pediatric patients with renal impairment.1
Clcr (mL/min) |
Daily Dosage |
---|---|
26–50 |
usual dose every 12 hours |
10–25 |
50% of usual dose every 12 hours |
<10 |
50% of usual dose once every 24 hours |
Manufacturer states data insufficient to make dosage recommendations in patients undergoing hemodialysis or peritoneal dialysis.1 Meropenem removed by hemodialysis; some clinicians suggest that supplemental doses be given after each hemodialysis session.47 48 Also removed by various forms of continuous renal replacement therapy, including continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemofiltration (CVVHF), and continuous ambulatory peritoneal dialysis (CAPD).49 50 51 52 53 To avoid inadequate concentrations in anuric patients undergoing these procedures, some clinicians suggest dosage adjustments are necessary and should be based on characteristics of the specific procedure (e.g., filter or membrane type, amount of filtrate produced, dialysate flow rate).49 50 51 52 53
Geriatric Patients
No dosage adjustments except those related to renal impairment.1 (See Renal Impairment under Dosage and Administration.)
Cautions for Meropenem
Contraindications
-
Known hypersensitivity to meropenem, other carbapenems, or any ingredient in the formulation.1
-
History of anaphylactic reaction to β-lactams.1
Warnings/Precautions
Warnings
Superinfection/Clostridium difficile-associated Colitis
Possible emergence and overgrowth of nonsusceptible organism.1 Careful observation of the patient is essential.1 Institute appropriate therapy if superinfection occurs.1
Treatment with anti-infectives may permit overgrowth of clostridia.1 Consider Clostridium difficile-associated diarrhea and colitis (antibiotic-associated pseudomembranous colitis) if diarrhea develops and manage accordingly.1
Some mild cases of C. difficile-associated diarrhea and colitis may respond to discontinuance alone.1 56 57 58 59 Manage moderate to severe cases with fluid, electrolyte, and protein supplementation; appropriate anti-infective therapy (e.g., oral metronidazole or vancomycin) recommended if colitis is severe.1 56 57 58 59
CNS Effects
Seizures and other CNS effects reported, especially in those with CNS disorders (e.g., brain lesions, history of seizures) or with bacterial meningitis and/or renal impairment.1
Do not exceed recommended dosage, especially in those with known factors that predispose to seizures.1 Anticonvulsant therapy should be continued in those with known seizure disorders.1
If focal tremors, myoclonus, or seizures occur, evaluate the patient neurologically, initiate anticonvulsant therapy if necessary, and determine whether meropenem dosage should be decreased or the drug discontinued.1
Sensitivity Reactions
Hypersensitivity Reactions
Serious and occasionally fatal hypersensitivity reactions (e.g., anaphylaxis) reported with β-lactams.1
If hypersensitivity occurs, discontinue meropenem and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, and maintenance of an adequate airway and oxygen).1
Cross-hypersensitivity
Partial cross-allergenicity among β-lactam antibiotics, including penicillins, cephalosporins, and other β-lactams.1
Prior to initiation of therapy, make careful inquiry concerning previous hypersensitivity reactions to meropenem, cephalosporins, penicillins, or other drugs.1
General Precautions
Selection and Use of Anti-infectives
To reduce development of drug-resistant bacteria and maintain effectiveness of meropenem and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.1
When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.1 In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.1
Laboratory Monitoring
Periodically assess organ system functions, including renal, hepatic, and hematopoietic, during prolonged therapy.1
Sodium Content
Each g of meropenem contains 3.92 mEq (90.2 mg) of sodium as sodium carbonate.1
Specific Populations
Pregnancy
Category B.1
Lactation
Not known whether distributed into milk.1 Use with caution.1
Pediatric Use
Safety and efficacy not established in children <3 months of age.1
Geriatric Use
No substantial differences in safety and efficacy relative to younger adults, but increased sensitivity cannot be ruled out.1
Substantially eliminated by kidneys; risk of toxicity may be greater in patients with impaired renal function.1 Select dosage with caution and assess renal function periodically since geriatric patients are more likely to have renal impairment.1
No dosage adjustments except those related to renal function.1 (See Renal Impairment under Dosage and Administration.)
Hepatic Impairment
Pharmacokinetics not affected by hepatic impairment; dosage adjustments not required.1
Renal Impairment
Decreased clearance.1 Dosage adjustments recommended in patients with Clcr ≤50 mL/minute.1 (See Renal Impairment under Dosage and Administration.)
Common Adverse Effects
GI effects (diarrhea, nausea, vomiting, constipation), local reactions (pain and inflammation at injection site, phlebitis/thrombophlebitis), headache, anemia, rash, pruritus, sepsis, apnea, shock, glossitis, oral candidiasis.1
Drug Interactions
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
Aminoglycosides |
In vitro evidence of synergistic antibacterial effects against Ps. aeruginosa1 |
|
Probenecid |
Decreased renal tubular secretion of meropenem; increased meropenem concentrations and AUC and prolonged half-life1 |
Concomitant use not recommended1 |
Valproic acid |
Valproic serum concentrations may be decreased to subtherapeutic concentrations; possible increased risk of seizures1 35 36 37 |
Meropenem Pharmacokinetics
Distribution
Extent
Well distributed into body tissues and fluids, including bronchial mucosa, lung, bile, gynecologic tissue (endometrium, myometrium, ovary, cervix, fallopian tube), muscle, heart valves, skin, and interstitial and peritoneal fluid.1
Distributed into CSF.1
Plasma Protein Binding
Approximately 2%.1
Elimination
Metabolism
Partially metabolized; at least 1 metabolite is microbiologically active.1
Elimination Route
Eliminated in urine as unchanged drug.1 70% of an IV dose eliminated in urine as unchanged drug.1
Half-life
Adults with normal renal function: approximately 1 hour.1
Children 3 months to 2 years of age: approximately 1.5 hours.1
Special Populations
Pharmacokinetics not affected by hepatic impairment.1
Decreased clearance in patients with renal impairment.1
Stability
Storage
Parenteral
Powder for Injection
20–25°C.1 Do not freeze reconstituted or diluted solutions.1
Solutions for IV injection containing approximately 50 mg/mL prepared using water for injection are stable for 2 hours at 15–25°C or 12 hours at 4°C.1
Solutions for IV infusion containing 2.5–50 mg/mL prepared using 0.9% sodium chloride are stable for up to 2 hours at 15–25°C or 18 hours at 4°C; those prepared using 5% dextrose are stable for up to 1 hour at 15–25°C or 8 hours at 4°C.1 1
Compatibility
Parenteral
Solution CompatibilityHID
Incompatible (by conventional definition, but recommended for dilution with use in shorter periods of time) |
Dextrose 5% with potassium chloride 0.15% |
Dextrose 5% in Ringer’s injection, lactated |
Dextrose 5% with sodium bicarbonate 0.02% |
Dextrose 2.5% in sodium chloride 0.45% |
Dextrose 5% in sodium chloride 0.2 or 0.9% |
Dextrose 5 or 10% in water |
Mannitol 2.5 or 10% |
Normosol M with dextrose 5% |
Ringer’s injection |
Ringer’s injection, lactated |
Sodium bicarbonate 5% |
Sodium chloride 0.45% |
Sodium lactate (1/6) M |
Variable |
---|
Sodium chloride 0.9% |
Drug Compatibility
Compatible |
---|
Aminophylline |
Atropine sulfate |
Dexamethasone sodium phosphate |
Dobutamine HCl |
Dopamine HCl |
Enalaprilat |
Fluconazole |
Furosemide |
Gentamicin sulfate |
Heparin sodium |
Insulin, regular |
Magnesium sulfate |
Metoclopramide HCl |
Morphine sulfate |
Norepinephrine bitartrate |
Phenobarbital sodium |
Ranitidine HCl |
Vancomycin HCl |
Incompatible |
Amphotericin B |
Multivitamins |
Variable |
Acyclovir sodium |
Doxycycline hyclate |
Ondansetron HCl |
Zidovudine |
Compatible |
---|
Aminophylline |
Anidulafungin |
Atropine sulfate |
Caspofungin acetate |
Cyclosporine |
Dexamethasone sodium phosphate |
Digoxin |
Diphenhydramine HCl |
Docetaxel |
Enalaprilat |
Fluconazole |
Furosemide |
Gentamicin sulfate |
Heparin sodium |
Insulin, regular |
Linezolid |
Metoclopramide HCl |
Milrinone lactate |
Morphine sulfate |
Norepinephrine bitartrate |
Phenobarbital sodium |
Potassium chloride |
Telavancin HCl |
Vancomycin HCl |
Vasopressin |
Incompatible |
Amphotericin B |
Diazepam |
Variable |
Acyclovir sodium |
Calcium gluconate |
Doxycycline hyclate |
Ondansetron HCl |
Zidovudine |
Actions and Spectrum
-
Synthetic carbapenem β-lactam antibiotic; structurally and pharmacologically related to imipenem and ertapenem.1 2 3
-
Usually bactericidal in action.1
-
Like other β-lactam antibiotics, antibacterial activity results from inhibition of bacterial cell wall synthesis.1
-
Spectrum of activity includes many gram-positive and -negative aerobic bacteria and some gram-positive and -negative anaerobic bacteria.1 Stable in the presence of a variety of β-lactamases (including penicillinases, cephalosporinases, and extended-spectrum β-lactamases).1
-
Gram-positive aerobes: Active in vitro and in clinical infections against Streptococcus pneumoniae (penicillin-susceptible strains only) and viridans streptococci.1 Also active in vitro against Staphylococcus aureus and S. epidermidis.1 Oxacillin-resistant (methicillin-resistant) staphylococci are resistant.1
-
Gram-negative aerobes: Active in vitro and in clinical infections against Escherichia coli, Haemophilus influenzae (including β-lactamase-producing strains), Klebsiella pneumoniae, Neisseria meningitidis and Pseudomonas aeruginosa.1 Also active in vitro against Acinetobacter, Aeromonas hydrophila, Campylobacter jejuni, Citrobacter, Enterobacter, H. influenzae (ampicillin-resistant, non-β-lactamase-producing strains; BLNAR), Havnia alvei, K. oxytoca, Moraxella catarrhalis, Morganella morganii, Pasteurella multocida, Proteus mirabilis, P. vulgaris, Salmonella, Shigella, Serratia marcescens, and Yersinia enterocolitica.1
-
Anaerobes: Active in vitro and in clinical infections against Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus.1 Also active in vitro against B. distasonis, B. ovatus, B. uniformis, B. ureolyticus, B. vulgatus, Clostridium difficile, C. perfringens, Eubacterium lentum, Fusobacterium, Prevotella bivia, P. intermedia, P. melaninogenica, Porphyromonas asaccharolytica, and Propionibacterium acnes.1
Advice to Patients
-
Advise patients that antibacterials (including meropenem) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).1
-
Importance of completing full course of therapy, even if feeling better after a few days.1
-
Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with meropenem or other antibacterials in the future.1
-
Importance of informing clinicians of other medical conditions, including history of seizures.1
-
Importance of discontinuing therapy and informing clinician if an allergic or hypersensitivity reaction occurs.1
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
-
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Parenteral |
For injection, for IV use only |
500 mg (of anhydrous meropenem) |
Merrem I.V. |
AstraZeneca |
1 g (of anhydrous meropenem) |
Merrem I.V. |
AstraZeneca |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions July 10, 2013. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. AstraZeneca Pharmaceuticals. Merrem IV (meropenem) for injection for intravenous use only prescribing information. Wilmington, DE; 2005 May.
2. Wiseman LR, Wagstaff AJ, Brogden RN et al. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1995; 50:73-101. http://www.ncbi.nlm.nih.gov/pubmed/7588092?dopt=AbstractPlus
3. Pryka RD, Haig GM. Meropenem: a new carbapenem antimicrobial. Ann Pharmacother. 1994; 28:1045-54. http://www.ncbi.nlm.nih.gov/pubmed/7803882?dopt=AbstractPlus
4. Condon RE, Walker AP, Sirinek KR et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis. 1995; 21:544-50. http://www.ncbi.nlm.nih.gov/pubmed/8527541?dopt=AbstractPlus
5. Brismar B, Malmborg AS, Tunevall G et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother. 1995; 35:139-48. http://www.ncbi.nlm.nih.gov/pubmed/7768761?dopt=AbstractPlus
6. Geroulanos SJ and the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother. 1995; 36(Suppl A):191-205. http://www.ncbi.nlm.nih.gov/pubmed/8543495?dopt=AbstractPlus
7. Huizinga WKJ, Warren BL, Baker LW et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother. 1995; 36(Suppl A):179-89. http://www.ncbi.nlm.nih.gov/pubmed/8543493?dopt=AbstractPlus
8. Klugman KP, Dagan R, and the Meropenem Meningitis Study Group. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother. 1995; 39:1140-6. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=162697&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/7625802?dopt=AbstractPlus
9. Anonymous. Meropenem—an advatageous antibiotic? Drug and Therapeutics Bulletin. 1996; 34:53-5.
10. Bradley JS, Faulkner KL, Klugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J. 1996; 15:749-57. http://www.ncbi.nlm.nih.gov/pubmed/8858694?dopt=AbstractPlus
11. Fukasawa M, Sumita Y, Harabe ET et al. Stability of meropenem and effect of 1β- methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother. 1992; 36:1577-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=191626&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1510457?dopt=AbstractPlus
12. Briceland LL, Tobin EH. Focus on meropenem: a broad-spectrum parenteral carbapenem antimicrobial agent. Formulary. 1996; 31:759-74.
13. Zeneca Pharmaceuticals, Wilmington, DE: Personal communication.
14. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34:730-51. http://www.ncbi.nlm.nih.gov/pubmed/11850858?dopt=AbstractPlus
15. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993; 328:1323-32. http://www.ncbi.nlm.nih.gov/pubmed/8469254?dopt=AbstractPlus
16. Ramphal R, Gucalp R, Rotstein C et al. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med. 1996; 100(Suppl 6A):83S-89S. http://www.ncbi.nlm.nih.gov/pubmed/8678102?dopt=AbstractPlus
17. Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother. 1998; 41(Suppl D):65-80. http://www.ncbi.nlm.nih.gov/pubmed/9688453?dopt=AbstractPlus
18. Rolston KV. Expanding the options for risk-based therapy in febrile neutropenia. Diagn Microbiol Infect Dis. 1998; 31:411-6. http://www.ncbi.nlm.nih.gov/pubmed/9635917?dopt=AbstractPlus
19. Bartlett JG, Dowell SF, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000; 31:347-82. http://www.ncbi.nlm.nih.gov/pubmed/10987697?dopt=AbstractPlus
20. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001; 163:1730-54. http://www.ncbi.nlm.nih.gov/pubmed/11401897?dopt=AbstractPlus
21. Bartoloni A, Strohmeyer M, Corti G et al. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp Clin Res. 1999; 25:243-52. http://www.ncbi.nlm.nih.gov/pubmed/10713862?dopt=AbstractPlus
22. Alvarez Lerma F and the Serious Infection Study Group. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother. 2001; 13:70-81. http://www.ncbi.nlm.nih.gov/pubmed/11233804?dopt=AbstractPlus
23. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003; 37:1405-33. http://www.ncbi.nlm.nih.gov/pubmed/14614663?dopt=AbstractPlus
24. Anon. Choice of antibacterial drugs. Med Lett Treat Guid. 2004; 2:18-26.
25. Committee on Infectious Diseases, American Academy of Pediatrics. Red book: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.
26. Anon. Drugs for pneumonia. Med Lett Treat Guid. 2003; 1:83-8.
27. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416. http://www.ncbi.nlm.nih.gov/pubmed/15699079?dopt=AbstractPlus
28. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003; 37:997-1005. http://www.ncbi.nlm.nih.gov/pubmed/14523762?dopt=AbstractPlus
29. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004; 39:1267-84. http://www.ncbi.nlm.nih.gov/pubmed/15494903?dopt=AbstractPlus
30. Yogev R, Guzman-Cottrill J. Bacterial meningitis in children. Critical review of current concepts. Drugs. 2005; 65:1097-112. http://www.ncbi.nlm.nih.gov/pubmed/15907145?dopt=AbstractPlus
31. US Army Medical Research Institute of Infectious Disease. USAMRIID’s medical management of biologic casualties handbook. 5th ed. USAMRIID: Fort Detrick, MD; 2004 Aug:32-8,D2.
32. Cheng AC, Fisher DA, Anstey NM et al. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother. 2004; 48:1763-5. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=400582&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/15105132?dopt=AbstractPlus
33. Currie BJ. Melioidosis: an important cause of pneumonia in residents of and travelers returned from endemic regions. Eur Respir J. 2003; 22:542-50. http://www.ncbi.nlm.nih.gov/pubmed/14516149?dopt=AbstractPlus
34. Bossi P, Tegnell A, Baka A et al. BICHAT guidelines for the clinical management of glanders and melioidosis and bioterrorism-related glanders and melioidosis. Euro Surveill. 2004; 9:1-6.
35. Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol. 2004; 31:232-4. http://www.ncbi.nlm.nih.gov/pubmed/15351028?dopt=AbstractPlus
36. Santucci M, Parmeggiani A, Riva R. Seizure worsening caused by decreased serum valproate during meropenem therapy. J Child Neurol. 2005; 20:456-7. http://www.ncbi.nlm.nih.gov/pubmed/15968935?dopt=AbstractPlus
37. Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A et al. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother. 2005; 39:533-7. http://www.ncbi.nlm.nih.gov/pubmed/15701769?dopt=AbstractPlus
38. Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis. 1995; 21:86-92. http://www.ncbi.nlm.nih.gov/pubmed/7578765?dopt=AbstractPlus
39. Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis. 2005; 5:287-95. http://www.ncbi.nlm.nih.gov/pubmed/15854884?dopt=AbstractPlus
40. Drago L, De Vecchi E, Lombardi A et al. Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates. J Antimicrob Chemother. 2002; 50:1059-63. http://www.ncbi.nlm.nih.gov/pubmed/12461034?dopt=AbstractPlus
41. Inglesby TV, O’Toole T, Henderson DA et al for the Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002; 287:2236-52. http://www.ncbi.nlm.nih.gov/pubmed/11980524?dopt=AbstractPlus
42. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001; 50:909-19. http://www.ncbi.nlm.nih.gov/pubmed/11699843?dopt=AbstractPlus
43. Zanetti G, Harbarth SJ, Trampuz A et al. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Int J Antimicrob Agents. 1999; 11:107-13. http://www.ncbi.nlm.nih.gov/pubmed/10221413?dopt=AbstractPlus
44. Odio CM, Puig JR, Feris JM et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J. 1999; 18:581-90. http://www.ncbi.nlm.nih.gov/pubmed/10440432?dopt=AbstractPlus
45. Vandecasteele SJ, Verhaegen J, Colaert J et al. Failure of cefotaxime and meropenem to eradicate meningitis caused by an intermediately susceptible Streptococcus pneumoniae strain. Eur J Clin Microbiol Infect Dis. 2001; 20:751-2. http://www.ncbi.nlm.nih.gov/pubmed/11757981?dopt=AbstractPlus
46. Schmutzhard E, Williams KJ, Vukmirovits G et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother. 1995; 36(suppl A):85-97. http://www.ncbi.nlm.nih.gov/pubmed/8543502?dopt=AbstractPlus
47. Chimata M, Nagase M, Suzuki Y et al. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother. 1993; 37:229-33. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=187644&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/8452352?dopt=AbstractPlus
48. Christensson BA, Nilsson-Ehle I, Hutchison M et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992; 36:1532-7. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=191616&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1510451?dopt=AbstractPlus
49. Krueger WA, Schroeder TH, Hutchison M et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother. 1998; 42:2421-4. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=105844&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9736574?dopt=AbstractPlus
50. Thalhammer F, Horl WH. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet. 2000; 39:271-9. http://www.ncbi.nlm.nih.gov/pubmed/11069213?dopt=AbstractPlus
51. Giles LJ, Jennings AC, Thomson AH et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med. 2000; 28:632-7. http://www.ncbi.nlm.nih.gov/pubmed/10752806?dopt=AbstractPlus
52. Robatel C, Decosterd LA, Biollaz J. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol. 2003; 43:1329-40. http://www.ncbi.nlm.nih.gov/pubmed/14615469?dopt=AbstractPlus
53. Valtonen M, Tiula E, Backman JT et al. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2000; 45:701-4. http://www.ncbi.nlm.nih.gov/pubmed/10797097?dopt=AbstractPlus
54. Reviewers’ comments (personal observations).
55. Ziemba. Wilmington, DE: Personal communication.
56. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998; 26:1027-36. http://www.ncbi.nlm.nih.gov/pubmed/9597221?dopt=AbstractPlus
57. Gerding DN, Johnson S, Peterson LR et al for the Society for Healthcare Epidemiology of America. Position paper on Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995; 16:459-77. http://www.ncbi.nlm.nih.gov/pubmed/7594392?dopt=AbstractPlus
58. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50. http://www.ncbi.nlm.nih.gov/pubmed/9149180?dopt=AbstractPlus
59. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm. 1998; 55:1407-11. http://www.ncbi.nlm.nih.gov/pubmed/9659970?dopt=AbstractPlus
60. Goldstein SL, Murry DJ, Aleksic SM et al. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. Pediatr Nephrol. 2001; 16:1015-8. http://www.ncbi.nlm.nih.gov/pubmed/11793091?dopt=AbstractPlus
HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:743-9.
c. Anon. The choice of antibacterial drugs. Med Lett Drugs Ther. 2001; 43:69-78. http://www.ncbi.nlm.nih.gov/pubmed/11518876?dopt=AbstractPlus
d. Committee on Infectious Diseases, American Academy of Pediatrics. 2000 Red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:161-2,182-3,196-8,364-5,411-2.
More about meropenem
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: carbapenems
- Breastfeeding
- En español